The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comprehensive reassessment of plasma VEGFA (pVEGFA) as a candidate predictive biomarker for bevacizumab (Bv) in 13 pivotal trials (seven indications).
Carlos Bais
Employment or Leadership Position - Roche/Genentech
Research Funding - Roche/Genentech
Christina Rabe
Employment or Leadership Position - Roche
Norbert Wild
Employment or Leadership Position - Roche
Magdalena Swiatek-de Lange
Employment or Leadership Position - Roche
David Chen
Employment or Leadership Position - Genentech
Stock Ownership - Roche
Kyu Hong
Employment or Leadership Position - Genentech
Stock Ownership - Genentech
Lukas Amler
Employment or Leadership Position - Genentech
Nicola Moore
Employment or Leadership Position - Roche
Priti S. Hegde
Employment or Leadership Position - Genentech